292 related articles for article (PubMed ID: 25728292)
1. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
Tamborini Permunian E; Riva N; Guasti L; Squizzato A
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
[TBL] [Abstract][Full Text] [Related]
2. Cangrelor for the treatment of patients with Arterial Thrombosis.
Tantry U; Chaudhary R; Kubica J; Bliden K; Gurbel PA
Expert Opin Pharmacother; 2018 Aug; 19(12):1389-1398. PubMed ID: 30102083
[TBL] [Abstract][Full Text] [Related]
3. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
4. Cangrelor for treatment of arterial thrombosis.
Walsh JA; Price MJ
Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
[TBL] [Abstract][Full Text] [Related]
5. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
[TBL] [Abstract][Full Text] [Related]
6. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
7. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA;
Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551
[TBL] [Abstract][Full Text] [Related]
8. Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH; Dobesh PP
Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
[TBL] [Abstract][Full Text] [Related]
9. Cangrelor: a review on pharmacology and clinical trial development.
Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
[TBL] [Abstract][Full Text] [Related]
10. Cangrelor for the management and prevention of arterial thrombosis.
Storey RF; Sinha A
Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):991-9. PubMed ID: 27362653
[TBL] [Abstract][Full Text] [Related]
11. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
12. Cangrelor for treatment of coronary thrombosis.
Fugate SE; Cudd LA
Ann Pharmacother; 2006 May; 40(5):925-30. PubMed ID: 16595568
[TBL] [Abstract][Full Text] [Related]
13. Cangrelor: A New Route for P2Y12 Inhibition.
Sible AM; Nawarskas JJ
Cardiol Rev; 2017; 25(3):133-139. PubMed ID: 28379902
[TBL] [Abstract][Full Text] [Related]
14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
15. Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM
Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue ML; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Deliargyris EN; Mahaffey KW; White HD; Harrington RA;
Circulation; 2016 Jan; 133(3):248-55. PubMed ID: 26762525
[TBL] [Abstract][Full Text] [Related]
17. Cangrelor: a novel P2Y12 receptor antagonist.
Norgard NB
Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
[TBL] [Abstract][Full Text] [Related]
18. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
Marcano AL; Ferreiro JL
Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of cangrelor in patients with suboptimal P2Y
Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Bowman S; Gass J; Weeks P
Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
